HCRN Lun19-427 (Small Cell Lung Cancer)

What is the Purpose of this Study?

This study has 2 parts: a screening period and a study dosing period.

If you join this study, during the screening period you will:
- Have blood draws
- Visit the clinic for various tests to see if you're eligible for the dosing period

If you're eligible for the dosing period, you will:
- Have blood draws
- Answer questionnaires
- Have imaging scans (CT and MRI)
- Receive chemotherapy drugs (carboplatin and etoposide) plus the study drug (atezolizumab) once every 3 weeks for 4 cycles (12 weeks total)
-- After the 4 cycles are done, you will receive only atezolizumab once every 3 weeks
What is the Condition Being Studied?
Small Cell Lung Cancer (SCLC) with untreated Brain Metastases

Who Can Participate in this Study?

Adults age 18 or older who:

- Are diagnosed with extensive stage SCLC

- Have untreated, asymptomatic brain metastases

For more information about who can be in this study, please contact the study team.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to see if combining chemotherapy (carboplatin and etoposide) with a study drug called atezolizumab can help people with extensive stage small cell lung cancer (SCLC) that has spread to the brain. We want to find out if this experimental drug combination can give patients more time before whole brain radiation is needed.

Study Details

Full Title
Chemotherapy and Atezolizumab for Patients with Extensive Stage Small Cell Lung Cancer (SCLC) with Untreated, Asymptomatic Brain Metastases (HCRN LUN19-427)
Principal Investigator

Contacts
Protocol Number
IRB:
PRO00106166

NCT:
NCT04610684
ClinicalTrials.gov
View on ClinicalTrials.gov